Yosuke Togashi
Overview
Explore the profile of Yosuke Togashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
4767
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fujimoto T, Yamasaki O, Kanehira N, Matsushita H, Sakurai Y, Kenmotsu N, et al.
Cancer Sci
. 2024 Aug;
115(10):3231-3247.
PMID: 39119813
Immune checkpoint inhibitors (ICIs) are effective against many advanced malignancies. However, many patients are nonresponders to immunotherapy, and overcoming this resistance to treatment is important. Boron neutron capture therapy (BNCT)...
12.
Okumura K, Morinaga T, Saito M, Tokunaga Y, Otoyama K, Tanaka S, et al.
Cancer Sci
. 2024 Jun;
115(8):2839-2845.
PMID: 38898727
By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1 has been considered to promote cancer...
13.
Tsukada Y, Bando H, Inamori K, Wakabayashi M, Togashi Y, Koyama S, et al.
Br J Cancer
. 2024 Jun;
131(2):283-289.
PMID: 38834744
Background: Preoperative chemoradiotherapy (CRT) followed by surgery is the standard treatment for locally advanced rectal cancer (LARC). We reported the short-term outcomes of the VOLTAGE trial that investigated the safety...
14.
Naoi Y, Morinaga T, Nagasaki J, Ariyasu R, Ueda Y, Yamashita K, et al.
Cancer Res
. 2024 Apr;
84(13):2109-2122.
PMID: 38635899
T-cell exhaustion is a major contributor to immunosuppression in the tumor microenvironment (TME). Blockade of key regulators of T-cell exhaustion, such as programmed death 1, can reinvigorate tumor-specific T cells...
15.
Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K, et al.
J Clin Invest
. 2024 Apr;
134(7).
PMID: 38557498
BACKGROUNDPrecise stratification of patients with non-small cell lung cancer (NSCLC) is needed for appropriate application of PD-1/PD-L1 blockade therapy.METHODSWe measured soluble forms of the immune-checkpoint molecules PD-L1, PD-1, and CTLA-4...
16.
Zhou W, Kawashima S, Ishino T, Kawase K, Ueda Y, Yamashita K, et al.
Cell Rep
. 2024 Feb;
43(2):113797.
PMID: 38363680
Immune checkpoint inhibitors exert clinical efficacy against various types of cancer through reinvigoration of exhausted CD8 T cells that attack cancer cells directly in the tumor microenvironment (TME). Using single-cell...
17.
Okumura K, Morinaga T, Saito M, Tokunaga Y, Otoyama K, Tanaka S, et al.
J Invest Dermatol
. 2024 Feb;
144(8):1890-1893.e5.
PMID: 38325578
No abstract available.
18.
Dansako H, Ikeda M, Ariumi Y, Togashi Y, Kato N
FEBS J
. 2023 Oct;
291(6):1119-1130.
PMID: 37863517
During the replication of viral genomes, RNA viruses produce double-stranded RNA (dsRNA), through the activity of their RNA-dependent RNA polymerases (RdRps) as viral replication intermediates. Recognition of viral dsRNA by...
19.
Ikeda H, Nagasaki J, Shimizu D, Katsuya Y, Horinouchi H, Hosomi Y, et al.
JTO Clin Res Rep
. 2023 Oct;
4(10):100573.
PMID: 37799325
Introduction: Unresectable or recurrent thymic epithelial tumors (TETs) have a poor prognosis, and treatment options are limited. This study aimed to investigate the immunologic significance of CD80/CD86 or major histocompatibility...
20.
Kemmotsu N, Ninomiya K, Kunimasa K, Ishino T, Nagasaki J, Otani Y, et al.
Int J Cancer
. 2023 Aug;
154(1):169-179.
PMID: 37611176
Intracranial metastases are common in nonsmall-cell lung cancer (NSCLC) patients, whose prognosis is very poor. In addition, intracranial progression is common during systemic treatments due to the inability to penetrate...